Full Text
Cost-Effectiveness of Nivolumab vs. Docetaxel as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Abstract

Authors

S Shah SE Matthews S Sarasani S Noel CM Blanchette

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×